Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan.
Kaiunbashi Endoscopy Clinic, Morioka, Japan.
Scand J Gastroenterol. 2021 Feb;56(2):199-204. doi: 10.1080/00365521.2020.1862906. Epub 2020 Dec 17.
Both potassium-competitive acid blockers (P-CABs) and proton pump inhibitors (PPIs) are known to be protective against bleeding after gastric endoscopic dissection (ESD) for early gastric cancers. The aim was to compare the effect of PPI and P-CAB treatment against bleeding after gastric ESD.
This was a single-center, retrospective analysis. Among 541 patients who underwent gastric ESD during the period from 2014 to 2019, we recruited subjects who were treated with PPIs (intravenous lansoprazole followed by oral esomeprazole) or a P-CAB before and after ESD. The incidence of post-ESD bleeding was compared between treatment groups. The risks associated with post-ESD bleeding were examined by univariate and multivariate analyses after propensity score-matching.
The overall incidence of post-ESD bleeding was not significantly different between patients treated with PPIs ( = 362) and those treated with a P-CAB ( = 156) (3.0% vs 2.6%, respectively; = .77). Even after propensity score matching ( = 153 in each group), the incidence was not significantly different between groups (2.6% vs 2.6%, respectively; = 1.00). A multivariate analysis revealed that antithrombotic therapy (OR 4.85, 95% CI 1.14-20.57) was an independent factor associated with post-ESD bleeding.
The incidence of post gastric ESD bleeding is not different between patients treated with PPI and patients treated with P-CAB. Antithrombotic therapy is an independent risk factor associated with post-ESD bleeding.
已知钾竞争性酸阻滞剂(P-CAB)和质子泵抑制剂(PPI)均能预防胃内镜下剥离术(ESD)治疗早期胃癌后的出血。本研究旨在比较 PPI 和 P-CAB 治疗对胃 ESD 后出血的影响。
这是一项单中心回顾性分析。在 2014 年至 2019 年期间接受胃 ESD 的 541 例患者中,我们招募了在 ESD 前后接受 PPI(静脉注射兰索拉唑,然后口服埃索美拉唑)或 P-CAB 治疗的患者。比较了两组患者 ESD 后出血的发生率。采用单因素和多因素分析,对倾向性评分匹配后与 ESD 后出血相关的风险因素进行了检查。
接受 PPI 治疗(n=362)和 P-CAB 治疗(n=156)的患者 ESD 后出血的总体发生率无显著差异(分别为 3.0%和 2.6%, = .77)。即使在进行倾向性评分匹配后(每组 n=153),两组间的发生率也无显著差异(分别为 2.6%和 2.6%, = 1.00)。多因素分析显示,抗血栓治疗(OR 4.85,95% CI 1.14-20.57)是与 ESD 后出血相关的独立因素。
接受 PPI 治疗和接受 P-CAB 治疗的患者 ESD 后出血的发生率无差异。抗血栓治疗是与 ESD 后出血相关的独立危险因素。